NEW YORK, May 17 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Global Pulmonary Drug Delivery Technologies industry
http://www.reportlinker.com/p0197151/Global-Pulmonary-Drug-Delivery-Technologies-industry.html
This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 61 companies including many key and niche players such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes, Inc., Aradigm Corporation, AstraZeneca Plc, Baxter International Inc., Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, NovartiS AG, Oriel Therapeutics, Inc., Sepracor, Inc., SkyePharma Plc, Valois S.A.S, and Vectura Group Plc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
PULMONARY DRUG DELIVERY TECHNOLOGIES MCP-1244
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Metered Dose Inhalers (MDIs) I-3
Dry Powder Inhalers (DPIs) I-4
Others I-4
Nebulizers I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Drug Delivery Technologies: A Primer II-1
Table 1: Worldwide Drug Delivery Market (2007): Percentage
Share Breakdown of Revenue by Technology Segment (includes
corresponding Graph/Chart) II-1
Drug Delivery Technologies Turns Critically Important to
Pharma Majors II-2
The Need for Novel Drug Delivery Technologies From A
Financial Standpoint II-2
Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug
Administration Route II-3
Market Fundamentals: A Current Review II-3
Respiratory Disorders: A Large & Mature Therapeutic Category II-4
Widely Prescribed Inhalation Drugs for Asthma & COPD II-5
Inhaler Devices: An Integral Part of Pulmonary Drug Delivery II-5
Pulmonary Delivery of Systemic Drugs: A Future Growth Area II-5
Delivering Macromolecules Through the Lungs: A Current Focus
Area II-6
Innovations in Inhalation Aerosols II-7
Current Drugs in Pipeline: A Review II-8
Inhaled Drugs in Pipeline as of the Year 2008 & 2009 II-8
Noteworthy Trends & Issues II-11
Nanotechnology Makes its Presence Felt in Inhaled Drugs II-11
Innovation in Inhaler Devices: A Key Differentiating Factor II-12
Innovation is the Name of the Game in the Nebulizer Segment II-12
Nebulizers for Pediatric Care: Need of the Hour II-13
CFC Propellants Give Way to HFA II-14
Chinks in MDI's Armor Work in Favor of DPI Market II-14
Potential Challenges for DPI Market II-14
Combination Therapy: An Effective Strategy in Optimum
Disease Management II-15
2. PRODUCT OVERVIEW II-16
Definition of Pulmonary Drug Delivery System II-16
Benefits of Pulmonary Drug Delivery Systems II-16
Therapeutic Benefits II-17
Titration by Therapy II-17
Titration by Patient II-17
Dose Reproducibility II-17
High Bioavailability II-17
Other Key Advantages II-18
Pulmonary Drug Delivery Devices II-18
An Overview of Key Features of Popular Inhalation Devices II-18
Inhalers II-18
Metered Dose Inhalers (MDIs) II-18
Working Principle of an MDI II-19
CFC-Propellant based MDIs II-20
Ban on CFCs II-20
Use of Spacers in MDIs II-20
Benefits of Spacers II-21
Pros & Cons II-21
Advantages II-21
Unique Benefits of pMDIs II-21
Limitations II-21
Issues II-22
MDIs & Future II-22
Dry Powder Inhalers (DPIs) II-22
Inspiratory Flow Rate in DPIs II-23
Working Principle of DPIs II-23
Deaggregation in Dry Powder Inhalers (DPIs) II-23
Types of DPIs II-24
Passive DPI II-24
Active DPI II-24
Single-dose DPIs II-24
Multi-dose DPIs II-24
Other Types II-24
Benefits of DPIs II-25
Limitations II-25
Issues II-25
In a nutshell II-26
Comparison with MDIs II-26
Nebulizers II-27
Working Principle of a Nebulizer II-27
Use of UDMs in Nebulizers II-28
Types of Nebulizers II-28
Ultrasonic Nebulizers II-28
Gray Areas II-28
Benefits II-29
Limitations II-29
Pneumatic Nebulizers II-29
Breath-Actuated Nebulizers II-29
Continuous Nebulization II-30
Active Venturi Nebulizers II-30
New Designs for Improved Nebulizer Performance II-30
Limitations of Nebulizers II-30
Factors Influencing Clinical Effectiveness of Inhalation Device II-31
Device Factors II-31
Patient Factors II-31
Drug Factors II-31
3. AN OVERVIEW OF PULMONARY CONDITIONS AND THERAPIES II-32
The Respiratory System II-32
Pulmonary Drug Delivery - An Overview II-32
Asthma and COPD - Major Respiratory Disease Conditions II-32
Asthma: Primary Respiratory Syndrome II-32
Trigger Factors II-33
Magnitude of Disease II-33
Chronic Obstructive Pulmonary Disease II-34
Magnitude of Disease II-34
Treatment of Asthma and COPD II-34
Methods of Drug Delivery through Pulmonary Route II-34
Aerosols Systems II-35
Intratracheal Inhalation II-35
Insufflation II-35
Pulmonary Delivery Approaches II-35
Controlled Release II-36
Drug Medications for Treating Asthma and COPD II-36
Bronchodilators (Acute Reliever Drugs) II-36
Categories of Bronchodilators II-37
Short acting beta-agonists II-37
Long acting beta-agonists II-37
Anti-cholinergics II-38
Methylxanthines II-39
Combination Bronchodilators II-40
Available Inhaled Locally Acting Drugs II-40
Anti-Inflammatory Medication (Controllers or Preventers) II-40
Corticosteroids II-41
Inhaled Corticosteroids in Asthma II-41
Inhaled Corticosteroids in COPD II-42
Anti-Leukotrienes II-42
Innovative Therapeutic Approaches II-42
Combination Therapeutics II-43
4. PRODUCT INNOVATIONS/INTRODUCTIONS II-44
Pearl Therapeutics Announces Phase II Trials of
Glycopyrrolate Inhalation Aerosol in COPD II-44
PARI Receives Patent for Vortex Holding Chamber II-44
Schering-Plough Obtains Approval for Asmanex in Japan II-44
SkyePharma Inc Receives FDA Communication on Flutiform II-44
Almirall Announces Positive Results of Phase III Eklira II-45
MicroDose Therapeutx Initiates Phase 1 Study with Inhaled
Atropine II-45
PARI Pharma Announces Successful Phase Ib Results for Inhaled
L-CsA II-45
PARI Respiratory Launches PEP S II-46
3M Drug Delivery Systems Rolls Out 3M Conix DPI, 3M Taper DPI II-46
Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN®
Phase III Study II-46
Vectura Group Announces Phase III Trials for NVA237, QVA149 II-46
Novartis Gets EU Approval for Onbrez® Breezhaler® II-47
Novartis Gets Complete Response Letter for QAB149, from US FDA II-47
Novartis Obtains EU Approval for Xolair® for Treating Severe
Asthma in Children Under 11 Years II-47
AstraZeneca Gets FDA Complete Response Letter for Symbicort
in Paediatric Patients II-47
AstraZeneca Gets FDA Approval for Symbicort in COPD II-48
3M Drug Delivery Systems Unveils 3M Face Seal Valve, 3M
Plasma Coating Technology II-48
Nanotechnology Victoria, Monash University Develops SAW
Generated Mechanism II-48
RTS Life Science Rolls Out Automated Inhaler Testing Solution II-49
Eli Lilly &Co and Alkermes Abandon Inhaled Insulin
Development Deal II-49
Novo-Nordisk Drops Development Plan of Inhaled Insulin II-49
Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate
to Relieve COPD Symptoms II-49
Advair Gets FDA Nod for Advair 250/50 II-50
5. RECENT INDUSTRY ACTIVITY II-51
Dainippon Sumitomo Concludes Acquisition of Sepracor II-51
MicroDose Therapeutx Acquires ViroPharma Investigational
Compounds II-51
Sepracor Grants Non-Exclusive License for XOPENEX® to Teva
and Barr II-51
Skyepharma, Novartis Terminate Formoterol Certihaler Deal II-51
Tidal Air to Sell Matrix Aerosol Delivery System II-51
Battelle Memorial Institute Purchases Assets of Ventaira
Pharmaceuticals Inc II-52
Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India II-52
3M Drug Delivery Systems Unveils New Singaporean Facility II-52
Forest Laboratories, Almirall, Extend Collaboration for
LAS100977 II-52
MicroDose Therapeutx, Merck Expand Collaboration Deal II-52
AstraZeneca Sells API Facility to Minakem II-52
ALR Technologies, Pari Enter Into Agreement II-53
Akela Adds Amendment Into Fentanyl TAIFUN® License Deal with
Teikoku Seiyaku II-53
Novartis, Schering-Plough Revise Collaboration Terms II-53
Astellas, AstraZeneca Ink Co-Promotion Agreement for
Symbicort Turbuhaler II-53
Iroko Cardio Inks Distribution Agreement with Chiesi
Farmaceutici II-53
Novartis Completes Acquisition of Nektar's Pulmonary Business II-54
3M, Cambridge Consultants Forge Licensing Deal for DPI
Technology II-54
Savara Relocates Headquarters to Texas II-54
GSK to Take Over Genelabs Technologies Inc II-54
Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm II-55
Sepracor Enters Into Agreement with Arrow International II-55
Royal Philips Electronics Acquires Medel, Melhk II-55
Aerogen Concludes Management Buyout from Nektar II-55
Valois Pharma Bags Multi Million Contract II-56
6. FOCUS ON SELECT PLAYERS II-57
3M Drug Delivery Systems Division (USA) II-57
Akela Pharma Inc (Canada) II-57
Alkermes, Inc. (USA) II-57
Aradigm Corporation (USA) II-58
AstraZeneca Plc (UK) II-58
Baxter International Inc. (USA) II-58
Chiesi Farmaceutici SpA (Italy) II-59
Consort Medical Plc (UK) II-60
Dey Pharma L.P. (USA) II-60
GlaxoSmithKline Plc (UK) II-61
Graceway Pharmaceuticals, LLC (USA) II-61
NovartiS AG (Switzerland) II-61
Oriel Therapeutics, Inc. (USA) II-62
Sepracor, Inc. (USA) II-62
SkyePharma Plc (UK) II-62
Valois S.A.S. (France) II-63
Vectura Group Plc (UK) II-63
7. GLOBAL MARKET PERSPECTIVE II-64
Table 2: World Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Geographic Region -
US, Canada, Japan, Europe, Asia Pacific (excluding Japan),
Latin America and Rest of the World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) II-64
Table 3: World Historic Review for Pulmonary Drug Delivery
Technologies by Geographic Region - US, Canada, Japan,
Europe, Asia Pacific (excluding Japan), Latin America and Rest
of the World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-65
Table 4: World 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-66
By Product Segments II-67
Table 5: World Recent Past, Current and Future Analysis for
Metered Dosage Inhalers (MDIs) by Geographic Region - US,
Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin
America and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) II-67
Table 6: World Historic Review for Metered Dosage Inhalers
(MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-68
Table 7: World 13-Year Perspective for Metered Dosage
Inhalers (MDIs) by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-69
Table 8: World Recent Past, Current and Future Analysis for
Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015(includes corresponding Graph/Chart) II-70
Table 9: World Historic Review for Dry Powder Inhalers (DPIs)
by Geographic Region - US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) II-71
Table 10: World 13-Year Perspective for Dry Powder Inhalers
(DPIs) by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia Pacific (excluding
Japan), Latin America and Rest of the World Markets for Years
2003, 2009, and 2015 (includes corresponding Graph/Chart) II-72
Table 11: World Recent Past, Current and Future Analysis for
Other Pulmonary Drug Delivery Technologies by Geographic
Region - US, Canada, Japan, Europe, Asia Pacific (excluding
Japan), Latin America and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-73
Table 12: World Historic Review for Other Pulmonary Drug
Delivery Technologies by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) II-74
Table 13: World 13-Year Perspective for Other Pulmonary Drug
Delivery Technologies by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-75
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Current Market Scenario III-1
Major Growth Areas/Indicators III-1
Respiratory Diseases III-1
Cancer III-2
Cystic Fibrosis III-2
HFA Albuterol Eats into CFC Inhalers Market III-2
Table 14: US Albuterol Inhalers Market in Aerosol Beta
Agonists Category (2006 & 2007): Percentage Share Breakdown
of Revenue by Product Type (includes corresponding
Graph/Chart) III-3
New & Popular DPIs in the US III-3
Nebulizers: Displaying Promising Growth III-3
Table 15: US Nebulizers Market (2008): Percentage Share
Breakdown of Revenues by Segment (includes corresponding
Graph/Chart) III-4
Role of FDA III-4
Key Market Share Findings III-4
Table 16: US Bronchodilators Market (2006): Percentage
Share Breakdown of Revenues by Key Players (includes
corresponding Graph/Chart) III-4
Table 17: US Anti-Inflammatory Market (2006): Percentage
Share Breakdown of Revenues by Key Players (includes
corresponding Graph/Chart) III-5
Table 18: US Bronchodilators Market (2009): Percentage
Share Breakdown of Revenues by Segment (includes
corresponding Graph/Chart) III-5
Table 19: US Anti-Inflammatory Market (2006): Percentage
Share Breakdown of Revenues by Segment (includes
corresponding Graph/Chart) III-5
Product Launches/Developments III-5
Strategic Corporate Developments III-8
Select Players III-11
B.Market Analytics III-14
Table 20: US Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-14
Table 21: US Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-15
Table 22: US 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015
(includes corresponding Graph/Chart) III-15
2. CANADA III-16
A.Market Analysis III-16
Outlook III-16
Product Launch III-16
Strategic Corporate Developments III-16
Akela Pharma Inc - A Key Canadian Player III-16
B.Market Analytics III-17
Table 23: Canadian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-17
Table 24: Canadian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-18
Table 25: Canadian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-18
3. JAPAN III-19
A.Market Analysis III-19
Outlook III-19
Product Launch III-19
Strategic Corporate Development III-19
B.Market Analytics III-20
Table 26: Japanese Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-20
Table 27: Japanese Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-21
Table 28: Japanese 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-21
4. EUROPE III-22
A.Market Analysis III-22
Outlook III-22
Growth Drivers III-22
Table 29: European Drug Delivery Market: Number of Deals
Between Pharmaceutical/ Biotechnology Companies and Drug
Delivery Companies for 2004 & 2007 III-23
Focus of R&D Shifts to Diabetes Treatment III-23
Table 30: Research Activity Distribution in the European
Pulmonary Drug Delivery Market (2007): Percentage Share
Breakdown of Activity by Therapeutic Area (includes
corresponding Graph/Chart) III-23
European Pulmonary Drug Delivery Market: Drugs In
Clinical Pipeline As of 2007 III-24
DPIs in Europe III-24
Product Launches/Developments III-25
Strategic Corporate Developments III-26
Novartis Ag (Switzerland) - A Key European Player III-27
B.Market Analytics III-28
Table 31: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest
of Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-28
Table 32: European Historic Review for Pulmonary Drug
Delivery Technologies by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-29
Table 33: European 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets for Years 2003,
2009 and 2015 (includes corresponding Graph/Chart) III-30
Table 34: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-31
Table 35: European Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-32
Table 36: European 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-33
4a. FRANCE III-34
A.Market Analysis III-34
Outlook III-34
Strategic Corporate Development III-34
Valois S.A.S. - A Key Player III-34
B.Market Analytics III-35
Table 37: French Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-35
Table 38: French Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-36
Table 39: French 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-36
4b. GERMANY III-37
Market Analysis III-37
Table 40: German Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-37
Table 41: German Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-38
Table 42: German 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-38
4c. ITALY III-39
A.Market Analysis III-39
Outlook III-39
Chiesi Farmaceutici SpA - A Key Player III-39
B.Market Analytics III-40
Table 43: Italian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-40
Table 44: Italian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-41
Table 45: Italian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-41
4d. THE UNITED KINGDOM III-42
A.Market Analysis III-42
Outlook III-42
Market Overview III-42
Areas of Growth III-42
Progress in Drug Delivery III-42
Product Launches/Developments III-43
Strategic Corporate Developments III-44
Select Players III-44
B.Market Analytics III-47
Table 46: UK Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-47
Table 47: UK Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-48
Table 48: UK 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015
(includes corresponding Graph/Chart) III-48
4e. SPAIN III-49
Market Analysis III-49
Table 49: Spanish Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-49
Table 50: Spanish Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-50
Table 51: Spanish 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-50
4f. RUSSIA III-51
Market Analysis III-51
Table 52: Russian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-51
Table 53: Russian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-52
Table 54: Russian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-52
4g. REST OF EUROPE III-53
Market Analysis III-53
Table 55: Rest of Europe Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-53
Table 56: Rest of Europe Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-54
Table 57: Rest of Europe 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-55
5. ASIA-PACIFIC III-56
A.Market Analysis III-56
Outlook III-56
Regional Snapshot III-56
India III-56
Nebulizers Market in India: A Quick Primer III-56
Dry Powder Inhalers for Children III-56
Product Launch III-56
Strategic Corporate Developments III-57
B.Market Analytics III-58
Table 58: Asia-Pacific Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-58
Table 59: Asia-Pacific Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-59
Table 60: Asia-Pacific 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-60
6. LATIN AMERICA III-61
Market Analysis III-61
Table 61: Latin American Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-61
Table 62: Latin American Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-62
Table 63: Latin American 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-63
7. REST OF WORLD III-64
Market Analysis III-64
Table 64: Rest of World Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-64
Table 65: Rest of World Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-65
Table 66: Rest of World 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-66
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 61 (including Divisions/Subsidiaries - 75)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 36
Canada 4
Japan 4
Europe 30
France 1
Germany 7
The United Kingdom 7
Italy 1
Spain 2
Rest of Europe 12
Middle East 1
------------------------------------------
To order this report:
Medical Equipment and Supply Industry: Global Pulmonary Drug Delivery Technologies industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Global Pulmonary Drug Delivery Technologies industry
http://www.reportlinker.com/p0197151/Global-Pulmonary-Drug-Delivery-Technologies-industry.html
Advertisement
This report analyzes the worldwide markets for Pulmonary Drug Delivery Technologies in US$ Million by the following Product Segments: Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs), and Others. The report provides separate comprehensive analytics for US, Canada, Japan, Europe, Asia Pacific, Latin America, and Rest of the World. Annual estimates and forecasts are provided for each region for the period 2007 through 2015. Also, a six-year historic analysis is provided for these markets. The report profiles 61 companies including many key and niche players such as 3M Drug Delivery Systems Division, Akela Pharma Inc., Alkermes, Inc., Aradigm Corporation, AstraZeneca Plc, Baxter International Inc., Chiesi Farmaceutici SpA, Consort Medical Plc, Dey Pharma L.P., GlaxoSmithKline Plc, Graceway Pharmaceuticals, LLC, NovartiS AG, Oriel Therapeutics, Inc., Sepracor, Inc., SkyePharma Plc, Valois S.A.S, and Vectura Group Plc. Market data and analytics are derived from primary and secondary research. Company profiles are mostly extracted from URL research and reported select online sources.
PULMONARY DRUG DELIVERY TECHNOLOGIES MCP-1244
A GLOBAL STRATEGIC BUSINESS REPORT
CONTENTS
I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation & Reporting Level I-2
Quantitative Techniques & Analytics I-3
Product Definitions and Scope of Study I-3
Metered Dose Inhalers (MDIs) I-3
Dry Powder Inhalers (DPIs) I-4
Others I-4
Nebulizers I-4
II. EXECUTIVE SUMMARY
1. INDUSTRY OVERVIEW II-1
Drug Delivery Technologies: A Primer II-1
Table 1: Worldwide Drug Delivery Market (2007): Percentage
Share Breakdown of Revenue by Technology Segment (includes
corresponding Graph/Chart) II-1
Drug Delivery Technologies Turns Critically Important to
Pharma Majors II-2
The Need for Novel Drug Delivery Technologies From A
Financial Standpoint II-2
Pulmonary Drug Delivery: A Preferred, Non-Invasive Drug
Administration Route II-3
Market Fundamentals: A Current Review II-3
Respiratory Disorders: A Large & Mature Therapeutic Category II-4
Widely Prescribed Inhalation Drugs for Asthma & COPD II-5
Inhaler Devices: An Integral Part of Pulmonary Drug Delivery II-5
Pulmonary Delivery of Systemic Drugs: A Future Growth Area II-5
Delivering Macromolecules Through the Lungs: A Current Focus
Area II-6
Innovations in Inhalation Aerosols II-7
Current Drugs in Pipeline: A Review II-8
Inhaled Drugs in Pipeline as of the Year 2008 & 2009 II-8
Noteworthy Trends & Issues II-11
Nanotechnology Makes its Presence Felt in Inhaled Drugs II-11
Innovation in Inhaler Devices: A Key Differentiating Factor II-12
Innovation is the Name of the Game in the Nebulizer Segment II-12
Nebulizers for Pediatric Care: Need of the Hour II-13
CFC Propellants Give Way to HFA II-14
Chinks in MDI's Armor Work in Favor of DPI Market II-14
Potential Challenges for DPI Market II-14
Combination Therapy: An Effective Strategy in Optimum
Disease Management II-15
2. PRODUCT OVERVIEW II-16
Definition of Pulmonary Drug Delivery System II-16
Benefits of Pulmonary Drug Delivery Systems II-16
Therapeutic Benefits II-17
Titration by Therapy II-17
Titration by Patient II-17
Dose Reproducibility II-17
High Bioavailability II-17
Other Key Advantages II-18
Pulmonary Drug Delivery Devices II-18
An Overview of Key Features of Popular Inhalation Devices II-18
Inhalers II-18
Metered Dose Inhalers (MDIs) II-18
Working Principle of an MDI II-19
CFC-Propellant based MDIs II-20
Ban on CFCs II-20
Use of Spacers in MDIs II-20
Benefits of Spacers II-21
Pros & Cons II-21
Advantages II-21
Unique Benefits of pMDIs II-21
Limitations II-21
Issues II-22
MDIs & Future II-22
Dry Powder Inhalers (DPIs) II-22
Inspiratory Flow Rate in DPIs II-23
Working Principle of DPIs II-23
Deaggregation in Dry Powder Inhalers (DPIs) II-23
Types of DPIs II-24
Passive DPI II-24
Active DPI II-24
Single-dose DPIs II-24
Multi-dose DPIs II-24
Other Types II-24
Benefits of DPIs II-25
Limitations II-25
Issues II-25
In a nutshell II-26
Comparison with MDIs II-26
Nebulizers II-27
Working Principle of a Nebulizer II-27
Use of UDMs in Nebulizers II-28
Types of Nebulizers II-28
Ultrasonic Nebulizers II-28
Gray Areas II-28
Benefits II-29
Limitations II-29
Pneumatic Nebulizers II-29
Breath-Actuated Nebulizers II-29
Continuous Nebulization II-30
Active Venturi Nebulizers II-30
New Designs for Improved Nebulizer Performance II-30
Limitations of Nebulizers II-30
Factors Influencing Clinical Effectiveness of Inhalation Device II-31
Device Factors II-31
Patient Factors II-31
Drug Factors II-31
3. AN OVERVIEW OF PULMONARY CONDITIONS AND THERAPIES II-32
The Respiratory System II-32
Pulmonary Drug Delivery - An Overview II-32
Asthma and COPD - Major Respiratory Disease Conditions II-32
Asthma: Primary Respiratory Syndrome II-32
Trigger Factors II-33
Magnitude of Disease II-33
Chronic Obstructive Pulmonary Disease II-34
Magnitude of Disease II-34
Treatment of Asthma and COPD II-34
Methods of Drug Delivery through Pulmonary Route II-34
Aerosols Systems II-35
Intratracheal Inhalation II-35
Insufflation II-35
Pulmonary Delivery Approaches II-35
Controlled Release II-36
Drug Medications for Treating Asthma and COPD II-36
Bronchodilators (Acute Reliever Drugs) II-36
Categories of Bronchodilators II-37
Short acting beta-agonists II-37
Long acting beta-agonists II-37
Anti-cholinergics II-38
Methylxanthines II-39
Combination Bronchodilators II-40
Available Inhaled Locally Acting Drugs II-40
Anti-Inflammatory Medication (Controllers or Preventers) II-40
Corticosteroids II-41
Inhaled Corticosteroids in Asthma II-41
Inhaled Corticosteroids in COPD II-42
Anti-Leukotrienes II-42
Innovative Therapeutic Approaches II-42
Combination Therapeutics II-43
4. PRODUCT INNOVATIONS/INTRODUCTIONS II-44
Pearl Therapeutics Announces Phase II Trials of
Glycopyrrolate Inhalation Aerosol in COPD II-44
PARI Receives Patent for Vortex Holding Chamber II-44
Schering-Plough Obtains Approval for Asmanex in Japan II-44
SkyePharma Inc Receives FDA Communication on Flutiform II-44
Almirall Announces Positive Results of Phase III Eklira II-45
MicroDose Therapeutx Initiates Phase 1 Study with Inhaled
Atropine II-45
PARI Pharma Announces Successful Phase Ib Results for Inhaled
L-CsA II-45
PARI Respiratory Launches PEP S II-46
3M Drug Delivery Systems Rolls Out 3M Conix DPI, 3M Taper DPI II-46
Akela Pharma Achieves Third Milestone in Fentanyl TAIFUN®
Phase III Study II-46
Vectura Group Announces Phase III Trials for NVA237, QVA149 II-46
Novartis Gets EU Approval for Onbrez® Breezhaler® II-47
Novartis Gets Complete Response Letter for QAB149, from US FDA II-47
Novartis Obtains EU Approval for Xolair® for Treating Severe
Asthma in Children Under 11 Years II-47
AstraZeneca Gets FDA Complete Response Letter for Symbicort
in Paediatric Patients II-47
AstraZeneca Gets FDA Approval for Symbicort in COPD II-48
3M Drug Delivery Systems Unveils 3M Face Seal Valve, 3M
Plasma Coating Technology II-48
Nanotechnology Victoria, Monash University Develops SAW
Generated Mechanism II-48
RTS Life Science Rolls Out Automated Inhaler Testing Solution II-49
Eli Lilly &Co and Alkermes Abandon Inhaled Insulin
Development Deal II-49
Novo-Nordisk Drops Development Plan of Inhaled Insulin II-49
Concomitant Use of Tiotropium, Nebulized Formoterol Fumarate
to Relieve COPD Symptoms II-49
Advair Gets FDA Nod for Advair 250/50 II-50
5. RECENT INDUSTRY ACTIVITY II-51
Dainippon Sumitomo Concludes Acquisition of Sepracor II-51
MicroDose Therapeutx Acquires ViroPharma Investigational
Compounds II-51
Sepracor Grants Non-Exclusive License for XOPENEX® to Teva
and Barr II-51
Skyepharma, Novartis Terminate Formoterol Certihaler Deal II-51
Tidal Air to Sell Matrix Aerosol Delivery System II-51
Battelle Memorial Institute Purchases Assets of Ventaira
Pharmaceuticals Inc II-52
Aptar Pharma to Roll Out Pulmonary & Nasal Devices In India II-52
3M Drug Delivery Systems Unveils New Singaporean Facility II-52
Forest Laboratories, Almirall, Extend Collaboration for
LAS100977 II-52
MicroDose Therapeutx, Merck Expand Collaboration Deal II-52
AstraZeneca Sells API Facility to Minakem II-52
ALR Technologies, Pari Enter Into Agreement II-53
Akela Adds Amendment Into Fentanyl TAIFUN® License Deal with
Teikoku Seiyaku II-53
Novartis, Schering-Plough Revise Collaboration Terms II-53
Astellas, AstraZeneca Ink Co-Promotion Agreement for
Symbicort Turbuhaler II-53
Iroko Cardio Inks Distribution Agreement with Chiesi
Farmaceutici II-53
Novartis Completes Acquisition of Nektar's Pulmonary Business II-54
3M, Cambridge Consultants Forge Licensing Deal for DPI
Technology II-54
Savara Relocates Headquarters to Texas II-54
GSK to Take Over Genelabs Technologies Inc II-54
Novo Nordisk Hand Over Inhaled Insulin Patents to Aradigm II-55
Sepracor Enters Into Agreement with Arrow International II-55
Royal Philips Electronics Acquires Medel, Melhk II-55
Aerogen Concludes Management Buyout from Nektar II-55
Valois Pharma Bags Multi Million Contract II-56
6. FOCUS ON SELECT PLAYERS II-57
3M Drug Delivery Systems Division (USA) II-57
Akela Pharma Inc (Canada) II-57
Alkermes, Inc. (USA) II-57
Aradigm Corporation (USA) II-58
AstraZeneca Plc (UK) II-58
Baxter International Inc. (USA) II-58
Chiesi Farmaceutici SpA (Italy) II-59
Consort Medical Plc (UK) II-60
Dey Pharma L.P. (USA) II-60
GlaxoSmithKline Plc (UK) II-61
Graceway Pharmaceuticals, LLC (USA) II-61
NovartiS AG (Switzerland) II-61
Oriel Therapeutics, Inc. (USA) II-62
Sepracor, Inc. (USA) II-62
SkyePharma Plc (UK) II-62
Valois S.A.S. (France) II-63
Vectura Group Plc (UK) II-63
7. GLOBAL MARKET PERSPECTIVE II-64
Table 2: World Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Geographic Region -
US, Canada, Japan, Europe, Asia Pacific (excluding Japan),
Latin America and Rest of the World Markets Independently
Analyzed with Annual Sales Figures in US$ Million for Years
2007 through 2015 (includes corresponding Graph/Chart) II-64
Table 3: World Historic Review for Pulmonary Drug Delivery
Technologies by Geographic Region - US, Canada, Japan,
Europe, Asia Pacific (excluding Japan), Latin America and Rest
of the World Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-65
Table 4: World 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-66
By Product Segments II-67
Table 5: World Recent Past, Current and Future Analysis for
Metered Dosage Inhalers (MDIs) by Geographic Region - US,
Canada, Japan, Europe, Asia Pacific (excluding Japan), Latin
America and Rest of the World Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2007
through 2015 (includes corresponding Graph/Chart) II-67
Table 6: World Historic Review for Metered Dosage Inhalers
(MDIs) by Geographic Region - US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) II-68
Table 7: World 13-Year Perspective for Metered Dosage
Inhalers (MDIs) by Geographic Region - Percentage Breakdown of
Dollar Sales for US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-69
Table 8: World Recent Past, Current and Future Analysis for
Dry Powder Inhalers (DPIs) by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2007 through
2015(includes corresponding Graph/Chart) II-70
Table 9: World Historic Review for Dry Powder Inhalers (DPIs)
by Geographic Region - US, Canada, Japan, Europe, Asia Pacific
(excluding Japan), Latin America and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) II-71
Table 10: World 13-Year Perspective for Dry Powder Inhalers
(DPIs) by Geographic Region - Percentage Breakdown of Dollar
Sales for US, Canada, Japan, Europe, Asia Pacific (excluding
Japan), Latin America and Rest of the World Markets for Years
2003, 2009, and 2015 (includes corresponding Graph/Chart) II-72
Table 11: World Recent Past, Current and Future Analysis for
Other Pulmonary Drug Delivery Technologies by Geographic
Region - US, Canada, Japan, Europe, Asia Pacific (excluding
Japan), Latin America and Rest of the World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2007 through 2015 (includes corresponding
Graph/Chart) II-73
Table 12: World Historic Review for Other Pulmonary Drug
Delivery Technologies by Geographic Region - US, Canada,
Japan, Europe, Asia Pacific (excluding Japan), Latin America
and Rest of the World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2001 through
2006 (includes corresponding Graph/Chart) II-74
Table 13: World 13-Year Perspective for Other Pulmonary Drug
Delivery Technologies by Geographic Region - Percentage
Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia
Pacific (excluding Japan), Latin America and Rest of the World
Markets for Years 2003, 2009, and 2015 (includes corresponding
Graph/Chart) II-75
III. MARKET
1. THE UNITED STATES III-1
A.Market Analysis III-1
Outlook III-1
Current Market Scenario III-1
Major Growth Areas/Indicators III-1
Respiratory Diseases III-1
Cancer III-2
Cystic Fibrosis III-2
HFA Albuterol Eats into CFC Inhalers Market III-2
Table 14: US Albuterol Inhalers Market in Aerosol Beta
Agonists Category (2006 & 2007): Percentage Share Breakdown
of Revenue by Product Type (includes corresponding
Graph/Chart) III-3
New & Popular DPIs in the US III-3
Nebulizers: Displaying Promising Growth III-3
Table 15: US Nebulizers Market (2008): Percentage Share
Breakdown of Revenues by Segment (includes corresponding
Graph/Chart) III-4
Role of FDA III-4
Key Market Share Findings III-4
Table 16: US Bronchodilators Market (2006): Percentage
Share Breakdown of Revenues by Key Players (includes
corresponding Graph/Chart) III-4
Table 17: US Anti-Inflammatory Market (2006): Percentage
Share Breakdown of Revenues by Key Players (includes
corresponding Graph/Chart) III-5
Table 18: US Bronchodilators Market (2009): Percentage
Share Breakdown of Revenues by Segment (includes
corresponding Graph/Chart) III-5
Table 19: US Anti-Inflammatory Market (2006): Percentage
Share Breakdown of Revenues by Segment (includes
corresponding Graph/Chart) III-5
Product Launches/Developments III-5
Strategic Corporate Developments III-8
Select Players III-11
B.Market Analytics III-14
Table 20: US Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-14
Table 21: US Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-15
Table 22: US 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015
(includes corresponding Graph/Chart) III-15
2. CANADA III-16
A.Market Analysis III-16
Outlook III-16
Product Launch III-16
Strategic Corporate Developments III-16
Akela Pharma Inc - A Key Canadian Player III-16
B.Market Analytics III-17
Table 23: Canadian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-17
Table 24: Canadian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-18
Table 25: Canadian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-18
3. JAPAN III-19
A.Market Analysis III-19
Outlook III-19
Product Launch III-19
Strategic Corporate Development III-19
B.Market Analytics III-20
Table 26: Japanese Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-20
Table 27: Japanese Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-21
Table 28: Japanese 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-21
4. EUROPE III-22
A.Market Analysis III-22
Outlook III-22
Growth Drivers III-22
Table 29: European Drug Delivery Market: Number of Deals
Between Pharmaceutical/ Biotechnology Companies and Drug
Delivery Companies for 2004 & 2007 III-23
Focus of R&D Shifts to Diabetes Treatment III-23
Table 30: Research Activity Distribution in the European
Pulmonary Drug Delivery Market (2007): Percentage Share
Breakdown of Activity by Therapeutic Area (includes
corresponding Graph/Chart) III-23
European Pulmonary Drug Delivery Market: Drugs In
Clinical Pipeline As of 2007 III-24
DPIs in Europe III-24
Product Launches/Developments III-25
Strategic Corporate Developments III-26
Novartis Ag (Switzerland) - A Key European Player III-27
B.Market Analytics III-28
Table 31: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Geographic
Region - France, Germany, Italy, UK, Spain, Russia and Rest
of Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-28
Table 32: European Historic Review for Pulmonary Drug
Delivery Technologies by Geographic Region - France,
Germany, Italy, UK, Spain, Russia and Rest of Europe Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-29
Table 33: European 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Geographic Region - Percentage
Breakdown of Dollar Sales for France, Germany, Italy, UK,
Spain, Russia and Rest of Europe Markets for Years 2003,
2009 and 2015 (includes corresponding Graph/Chart) III-30
Table 34: European Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-31
Table 35: European Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-32
Table 36: European 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-33
4a. FRANCE III-34
A.Market Analysis III-34
Outlook III-34
Strategic Corporate Development III-34
Valois S.A.S. - A Key Player III-34
B.Market Analytics III-35
Table 37: French Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-35
Table 38: French Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-36
Table 39: French 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-36
4b. GERMANY III-37
Market Analysis III-37
Table 40: German Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-37
Table 41: German Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-38
Table 42: German 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-38
4c. ITALY III-39
A.Market Analysis III-39
Outlook III-39
Chiesi Farmaceutici SpA - A Key Player III-39
B.Market Analytics III-40
Table 43: Italian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-40
Table 44: Italian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-41
Table 45: Italian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-41
4d. THE UNITED KINGDOM III-42
A.Market Analysis III-42
Outlook III-42
Market Overview III-42
Areas of Growth III-42
Progress in Drug Delivery III-42
Product Launches/Developments III-43
Strategic Corporate Developments III-44
Select Players III-44
B.Market Analytics III-47
Table 46: UK Recent Past, Current and Future Analysis for
Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs) and
Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-47
Table 47: UK Historic Review for Pulmonary Drug Delivery
Technologies by Product Segment - Metered Dose Inhalers
(MDIs), Dry Powder Inhalers (DPIs) and Other Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2001 through 2006 (includes corresponding
Graph/Chart) III-48
Table 48: UK 13-Year Perspective for Pulmonary Drug Delivery
Technologies by Product Segment - Percentage Breakdown of
Dollar Sales for Metered Dose Inhalers (MDIs), Dry Powder
Inhalers (DPIs) and Other Markets for 2003, 2009 and 2015
(includes corresponding Graph/Chart) III-48
4e. SPAIN III-49
Market Analysis III-49
Table 49: Spanish Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-49
Table 50: Spanish Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-50
Table 51: Spanish 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-50
4f. RUSSIA III-51
Market Analysis III-51
Table 52: Russian Recent Past, Current and Future Analysis
for Pulmonary Drug Delivery Technologies by Product Segment -
Metered Dose Inhalers (MDIs), Dry Powder Inhalers (DPIs)
and Other Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2007 through 2015 (includes
corresponding Graph/Chart) III-51
Table 53: Russian Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-52
Table 54: Russian 13-Year Perspective for Pulmonary Drug
Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-52
4g. REST OF EUROPE III-53
Market Analysis III-53
Table 55: Rest of Europe Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-53
Table 56: Rest of Europe Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-54
Table 57: Rest of Europe 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-55
5. ASIA-PACIFIC III-56
A.Market Analysis III-56
Outlook III-56
Regional Snapshot III-56
India III-56
Nebulizers Market in India: A Quick Primer III-56
Dry Powder Inhalers for Children III-56
Product Launch III-56
Strategic Corporate Developments III-57
B.Market Analytics III-58
Table 58: Asia-Pacific Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-58
Table 59: Asia-Pacific Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-59
Table 60: Asia-Pacific 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-60
6. LATIN AMERICA III-61
Market Analysis III-61
Table 61: Latin American Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-61
Table 62: Latin American Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-62
Table 63: Latin American 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-63
7. REST OF WORLD III-64
Market Analysis III-64
Table 64: Rest of World Recent Past, Current and Future
Analysis for Pulmonary Drug Delivery Technologies by Product
Segment - Metered Dose Inhalers (MDIs), Dry Powder Inhalers
(DPIs) and Other Markets Independently Analyzed with Annual
Sales Figures in US$ Million for Years 2007 through 2015
(includes corresponding Graph/Chart) III-64
Table 65: Rest of World Historic Review for Pulmonary Drug
Delivery Technologies by Product Segment - Metered Dose
Inhalers (MDIs), Dry Powder Inhalers (DPIs) and Other
Markets Independently Analyzed with Annual Sales Figures in
US$ Million for Years 2001 through 2006 (includes
corresponding Graph/Chart) III-65
Table 66: Rest of World 13-Year Perspective for Pulmonary
Drug Delivery Technologies by Product Segment - Percentage
Breakdown of Dollar Sales for Metered Dose Inhalers (MDIs),
Dry Powder Inhalers (DPIs) and Other Markets for 2003, 2009
and 2015 (includes corresponding Graph/Chart) III-66
IV. COMPETITIVE LANDSCAPE
Total Companies Profiled: 61 (including Divisions/Subsidiaries - 75)
------------------------------------------
Region/Country Players
------------------------------------------
The United States 36
Canada 4
Japan 4
Europe 30
France 1
Germany 7
The United Kingdom 7
Italy 1
Spain 2
Rest of Europe 12
Middle East 1
------------------------------------------
To order this report:
Medical Equipment and Supply Industry: Global Pulmonary Drug Delivery Technologies industry
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
